Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscular Dystrophy, Duchenne | 8 | 2025 | 41 | 4.950 |
Why?
|
| Muscle, Skeletal | 8 | 2023 | 741 | 1.240 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 2175 | 1.040 |
Why?
|
| Optical Imaging | 2 | 2017 | 71 | 0.960 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2024 | 2 | 0.900 |
Why?
|
| Vulnerable Populations | 1 | 2025 | 90 | 0.870 |
Why?
|
| Nervous System Diseases | 1 | 2024 | 107 | 0.760 |
Why?
|
| Hypohidrosis | 1 | 2021 | 4 | 0.740 |
Why?
|
| Syringomyelia | 1 | 2021 | 3 | 0.740 |
Why?
|
| Flushing | 1 | 2021 | 3 | 0.740 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2021 | 5 | 0.740 |
Why?
|
| Paresis | 1 | 2021 | 15 | 0.740 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2021 | 21 | 0.730 |
Why?
|
| Apnea | 1 | 2021 | 32 | 0.710 |
Why?
|
| Medicaid | 1 | 2025 | 362 | 0.700 |
Why?
|
| Neonatal Screening | 1 | 2021 | 98 | 0.680 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 564 | 0.650 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2020 | 294 | 0.600 |
Why?
|
| Pregnenediones | 1 | 2018 | 3 | 0.570 |
Why?
|
| Stair Climbing | 1 | 2017 | 1 | 0.550 |
Why?
|
| Sarcoglycans | 1 | 2017 | 4 | 0.530 |
Why?
|
| Muscular Dystrophies | 1 | 2017 | 11 | 0.520 |
Why?
|
| Indocyanine Green | 1 | 2016 | 10 | 0.510 |
Why?
|
| Coloring Agents | 1 | 2016 | 54 | 0.500 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 172 | 0.500 |
Why?
|
| Mice, Inbred mdx | 4 | 2023 | 15 | 0.420 |
Why?
|
| Child | 4 | 2025 | 4526 | 0.390 |
Why?
|
| Disease Progression | 3 | 2023 | 1172 | 0.280 |
Why?
|
| Humans | 12 | 2025 | 63445 | 0.260 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2024 | 5 | 0.230 |
Why?
|
| Acute Disease | 3 | 2021 | 671 | 0.220 |
Why?
|
| Genetic Therapy | 2 | 2024 | 791 | 0.210 |
Why?
|
| Mice | 5 | 2023 | 10844 | 0.210 |
Why?
|
| Myography | 1 | 2023 | 1 | 0.200 |
Why?
|
| Electric Impedance | 1 | 2023 | 36 | 0.200 |
Why?
|
| Animals | 9 | 2023 | 20663 | 0.190 |
Why?
|
| Aging | 2 | 2019 | 745 | 0.180 |
Why?
|
| Wasting Syndrome | 1 | 2020 | 7 | 0.160 |
Why?
|
| Cachexia | 1 | 2020 | 9 | 0.160 |
Why?
|
| CRISPR-Cas Systems | 1 | 2024 | 361 | 0.160 |
Why?
|
| Muscular Diseases | 1 | 2020 | 50 | 0.160 |
Why?
|
| Eye Proteins | 1 | 2020 | 74 | 0.160 |
Why?
|
| Male | 6 | 2021 | 29891 | 0.160 |
Why?
|
| Gene Editing | 1 | 2024 | 321 | 0.160 |
Why?
|
| Public Health | 1 | 2021 | 187 | 0.160 |
Why?
|
| Muscular Dystrophy, Animal | 1 | 2019 | 5 | 0.150 |
Why?
|
| Metabolome | 1 | 2019 | 31 | 0.150 |
Why?
|
| Metabolomics | 1 | 2019 | 52 | 0.150 |
Why?
|
| Glycoproteins | 1 | 2020 | 187 | 0.150 |
Why?
|
| Liposomes | 2 | 2009 | 105 | 0.150 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 200 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2021 | 753 | 0.140 |
Why?
|
| Streptococcus anginosus | 1 | 2018 | 2 | 0.140 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2018 | 4 | 0.140 |
Why?
|
| Complement C1q | 1 | 2018 | 8 | 0.140 |
Why?
|
| Glomerulonephritis | 1 | 2018 | 32 | 0.140 |
Why?
|
| Complement C3 | 1 | 2018 | 59 | 0.140 |
Why?
|
| Streptococcal Infections | 1 | 2018 | 80 | 0.140 |
Why?
|
| Tendons | 1 | 2017 | 25 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 3396 | 0.140 |
Why?
|
| Abdominal Pain | 1 | 2018 | 102 | 0.130 |
Why?
|
| Leg | 1 | 2017 | 88 | 0.130 |
Why?
|
| Infant, Newborn | 1 | 2021 | 1358 | 0.130 |
Why?
|
| Fibrosis | 1 | 2017 | 160 | 0.130 |
Why?
|
| Dystrophin | 1 | 2017 | 31 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 455 | 0.130 |
Why?
|
| Lipids | 1 | 2019 | 315 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2018 | 176 | 0.130 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2016 | 11 | 0.130 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2016 | 42 | 0.130 |
Why?
|
| Microscopy | 1 | 2017 | 91 | 0.120 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2017 | 94 | 0.120 |
Why?
|
| Cardiomegaly | 1 | 2016 | 34 | 0.120 |
Why?
|
| Age Factors | 2 | 2017 | 1558 | 0.120 |
Why?
|
| Child, Preschool | 1 | 2021 | 1990 | 0.120 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 2187 | 0.120 |
Why?
|
| Myocytes, Cardiac | 1 | 2016 | 99 | 0.120 |
Why?
|
| Ventricular Remodeling | 1 | 2016 | 83 | 0.120 |
Why?
|
| Drug Delivery Systems | 2 | 2009 | 325 | 0.120 |
Why?
|
| Caloric Restriction | 1 | 2015 | 18 | 0.120 |
Why?
|
| Fasting | 1 | 2015 | 51 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2017 | 295 | 0.110 |
Why?
|
| Time Factors | 3 | 2016 | 3768 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1119 | 0.110 |
Why?
|
| Biomarkers | 1 | 2020 | 1408 | 0.110 |
Why?
|
| Contrast Media | 1 | 2017 | 426 | 0.110 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 268 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1147 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2015 | 298 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2015 | 259 | 0.100 |
Why?
|
| Energy Metabolism | 1 | 2015 | 379 | 0.090 |
Why?
|
| United States | 1 | 2025 | 7843 | 0.090 |
Why?
|
| Genetic Vectors | 1 | 2017 | 879 | 0.080 |
Why?
|
| Adolescent | 1 | 2021 | 6245 | 0.080 |
Why?
|
| Tunica Intima | 1 | 2009 | 15 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2009 | 48 | 0.080 |
Why?
|
| Papaverine | 1 | 2008 | 7 | 0.080 |
Why?
|
| Fluoresceins | 1 | 2008 | 30 | 0.070 |
Why?
|
| Sonication | 1 | 2008 | 15 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 2009 | 174 | 0.070 |
Why?
|
| Heart Failure | 1 | 2016 | 913 | 0.070 |
Why?
|
| Bayes Theorem | 1 | 2022 | 122 | 0.050 |
Why?
|
| MEF2 Transcription Factors | 1 | 2020 | 10 | 0.040 |
Why?
|
| Sarcolemma | 1 | 2020 | 10 | 0.040 |
Why?
|
| Diaphragm | 1 | 2020 | 22 | 0.040 |
Why?
|
| Muscular Atrophy | 1 | 2020 | 26 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 63 | 0.040 |
Why?
|
| Body Composition | 1 | 2020 | 152 | 0.040 |
Why?
|
| Regeneration | 1 | 2020 | 95 | 0.040 |
Why?
|
| Carbon-13 Magnetic Resonance Spectroscopy | 1 | 2019 | 2 | 0.040 |
Why?
|
| Running | 1 | 2020 | 84 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 61 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 319 | 0.040 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2020 | 111 | 0.040 |
Why?
|
| Azotemia | 1 | 2018 | 1 | 0.040 |
Why?
|
| Nephrotic Syndrome | 1 | 2018 | 7 | 0.040 |
Why?
|
| Nephritis | 1 | 2018 | 11 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 281 | 0.040 |
Why?
|
| Proteinuria | 1 | 2018 | 41 | 0.040 |
Why?
|
| Abdominal Wall | 1 | 2018 | 23 | 0.040 |
Why?
|
| Aftercare | 1 | 2018 | 76 | 0.030 |
Why?
|
| Microscopy, Interference | 1 | 2017 | 2 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 341 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 937 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2019 | 484 | 0.030 |
Why?
|
| Myosin Light Chains | 1 | 2016 | 8 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2017 | 257 | 0.030 |
Why?
|
| Cardiac Myosins | 1 | 2016 | 24 | 0.030 |
Why?
|
| Atrophy | 1 | 2016 | 83 | 0.030 |
Why?
|
| Myocardial Contraction | 1 | 2016 | 88 | 0.030 |
Why?
|
| Sarcomeres | 1 | 2016 | 51 | 0.030 |
Why?
|
| Sirtuin 3 | 1 | 2015 | 11 | 0.030 |
Why?
|
| Florida | 1 | 2015 | 48 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 74 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2016 | 127 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 284 | 0.030 |
Why?
|
| Calcium Signaling | 1 | 2016 | 157 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 161 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1235 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2020 | 1537 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 936 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2015 | 739 | 0.030 |
Why?
|
| Antioxidants | 1 | 2015 | 252 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2015 | 235 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2015 | 360 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 719 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 1207 | 0.020 |
Why?
|
| Female | 3 | 2020 | 32880 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 790 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 433 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2016 | 2109 | 0.020 |
Why?
|
| Ultrasonics | 1 | 2009 | 16 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2009 | 88 | 0.020 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2008 | 27 | 0.020 |
Why?
|
| Diffusion | 1 | 2008 | 82 | 0.020 |
Why?
|
| Biological Availability | 1 | 2009 | 200 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1617 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2008 | 265 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 5680 | 0.020 |
Why?
|
| Rats | 1 | 2009 | 1980 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 4694 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 17613 | 0.010 |
Why?
|
| Adult | 1 | 2015 | 16824 | 0.010 |
Why?
|